Across TCGA pan-cancer cohorts, SRSF9 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SRSF9 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in uterine carcinosarcoma (UCS), where higher SRSF9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SRSF9 expression acts as an unfavorable survival marker.
UCS are the cancer types where SRSF9 Mutation most reproducibly stratifies survival.